Protalix Biotherapeutics, Inc. (PLX)
2.73
+0.02
(+0.74%)
USD |
NYAM |
Oct 06, 16:00
2.725
0.00 (0.00%)
Pre-Market: 20:00
Protalix Biotherapeutics PS Ratio : 2.767 for Oct. 6, 2026
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| October 06, 2026 | 2.767 |
| October 05, 2026 | 2.747 |
| October 02, 2026 | 2.747 |
| October 01, 2026 | 2.716 |
| September 30, 2026 | 2.797 |
| September 29, 2026 | 2.726 |
| September 28, 2026 | 2.726 |
| September 25, 2026 | 2.757 |
| September 24, 2026 | 2.787 |
| September 23, 2026 | 2.838 |
| September 22, 2026 | 2.878 |
| September 21, 2026 | 2.787 |
| September 18, 2026 | 2.726 |
| September 17, 2026 | 2.737 |
| September 16, 2026 | 2.716 |
| September 15, 2026 | 2.696 |
| September 14, 2026 | 2.808 |
| September 11, 2026 | 2.676 |
| September 10, 2026 | 2.767 |
| September 09, 2026 | 2.706 |
| September 08, 2026 | 2.686 |
| September 04, 2026 | 2.706 |
| September 03, 2026 | 2.656 |
| September 02, 2026 | 2.625 |
| September 01, 2026 | 2.625 |
| Date | Value |
|---|---|
| August 31, 2026 | 2.605 |
| August 28, 2026 | 2.574 |
| August 27, 2026 | 2.645 |
| August 26, 2026 | 2.514 |
| August 25, 2026 | 2.432 |
| August 24, 2026 | 2.443 |
| August 21, 2026 | 2.412 |
| August 20, 2026 | 2.412 |
| August 19, 2026 | 2.382 |
| August 18, 2026 | 2.372 |
| August 17, 2026 | 2.321 |
| August 14, 2026 | 2.250 |
| August 13, 2026 | 2.392 |
| August 12, 2026 | 2.656 |
| August 11, 2026 | 2.463 |
| August 10, 2026 | 2.514 |
| August 07, 2026 | 2.493 |
| August 06, 2026 | 2.473 |
| August 05, 2026 | 2.473 |
| August 04, 2026 | 2.402 |
| August 03, 2026 | 2.352 |
| July 31, 2026 | 2.402 |
| July 30, 2026 | 2.301 |
| July 29, 2026 | 2.301 |
| July 28, 2026 | 2.362 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| Altimmune, Inc. | 10764.77 |
| Taysha Gene Therapies, Inc. | 274.93 |
| Humacyte, Inc. | 43.78 |
| Agenus, Inc. | 2.086 |
| Amgen, Inc. | 5.725 |
PS Ratio Related Metrics
| PE Ratio | 12.02 |
| PEG Ratio | 0.0581 |
| Price to Book Value | 3.080 |
| Price to Free Cash Flow | 29.09 |
| Price | 2.73 |
| Earnings Yield | 8.32% |
| Market Cap | 219.96M |
| PEGY Ratio | 0.0581 |
| Operating PE Ratio | 9.578 |
| Normalized PE Ratio | 12.03 |